fused azepinone cyclin dependent kinase/glycogen synthase kinase 3 beta inhibitors (NCI)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namefused azepinone cyclin dependent kinase/glycogen synthase kinase 3 beta inhibitors (NCI)
Drug Alias Namefused azepinone CDK/GSK3beta inhibitors (NCI)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase inhibitorsGlycogen synthase kinase-3 beta inhibitors
TargetsGlycogen synthase kinase-3 betaCyclin-dependent kinase
Therapy Area/IndicationsNerve DegenerationHeart DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsNerve DegenerationHeart DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A